115. A critical situational decision needs to be made about funding a large-scale randomized controlled trial for a new cancer therapy. Preliminary data shows promising but not statistically significant results, and the biostatistician highlights the preliminary trial’s low power. What is the urgency for further investment?

To immediately abandon the therapy.
To urgently consider the implications of low power (high risk of Type II error) and the need for a larger, adequately powered trial before discarding a potentially beneficial therapy.
To fund a smaller, less expensive trial.
To rely solely on the current non-significant p-value.

Comment